Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age

NCT03210246 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03210246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03210246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 17, 2017
Completion date
January 23, 2019
Enrollment
71 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinical trial ,phase i